ゼリア新薬工業の株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2024/01/31 | 2,026 | 2,051 | 2,024 | 2,051 | +18 | +0.9% | 47,000 |
2024/01/30 | 2,050 | 2,056 | 2,033 | 2,033 | -12 | -0.6% | 52,700 |
2024/01/29 | 2,031 | 2,046 | 2,031 | 2,045 | +17 | +0.8% | 40,300 |
2024/01/26 | 2,030 | 2,041 | 2,020 | 2,028 | -5 | -0.2% | 57,600 |
2024/01/25 | 2,020 | 2,034 | 2,019 | 2,033 | +15 | +0.7% | 51,000 |
2024/01/24 | 2,029 | 2,031 | 2,004 | 2,018 | -11 | -0.5% | 57,500 |
2024/01/23 | 2,026 | 2,048 | 2,025 | 2,029 | -1 | ±0% | 64,000 |
2024/01/22 | 2,023 | 2,035 | 2,023 | 2,030 | +9 | +0.4% | 39,100 |
2024/01/19 | 2,032 | 2,037 | 2,014 | 2,021 | -24 | -1.2% | 79,000 |
2024/01/18 | 2,040 | 2,048 | 2,030 | 2,045 | -2 | -0.1% | 51,500 |
2024/01/17 | 2,074 | 2,079 | 2,047 | 2,047 | -15 | -0.7% | 56,900 |
2024/01/16 | 2,080 | 2,083 | 2,061 | 2,062 | -16 | -0.8% | 43,400 |
2024/01/15 | 2,063 | 2,078 | 2,052 | 2,078 | +19 | +0.9% | 50,600 |
2024/01/12 | 2,070 | 2,074 | 2,050 | 2,059 | +5 | +0.2% | 65,200 |
2024/01/11 | 2,070 | 2,072 | 2,050 | 2,054 | -9 | -0.4% | 72,500 |
2024/01/10 | 2,050 | 2,073 | 2,040 | 2,063 | +16 | +0.8% | 67,300 |
2024/01/09 | 2,053 | 2,058 | 2,034 | 2,047 | +14 | +0.7% | 50,400 |
2024/01/05 | 2,065 | 2,068 | 2,029 | 2,033 | -12 | -0.6% | 52,200 |
2024/01/04 | 2,017 | 2,054 | 1,995 | 2,045 | +28 | +1.4% | 75,400 |
2023/12/29 | 2,020 | 2,027 | 2,005 | 2,017 | -1 | ±0% | 41,800 |
2023/12/28 | 2,009 | 2,018 | 1,999 | 2,018 | +8 | +0.4% | 52,000 |
2023/12/27 | 2,000 | 2,012 | 1,998 | 2,010 | +8 | +0.4% | 95,900 |
2023/12/26 | 2,000 | 2,012 | 1,997 | 2,002 | +7 | +0.4% | 71,000 |
2023/12/25 | 2,000 | 2,007 | 1,993 | 1,995 | +14 | +0.7% | 88,400 |
2023/12/22 | 1,970 | 1,983 | 1,970 | 1,981 | +19 | +1% | 53,200 |
2023/12/21 | 1,960 | 1,970 | 1,959 | 1,962 | -13 | -0.7% | 34,200 |
2023/12/20 | 1,960 | 1,979 | 1,959 | 1,975 | +22 | +1.1% | 54,000 |
2023/12/19 | 1,944 | 1,953 | 1,931 | 1,953 | +9 | +0.5% | 67,600 |
2023/12/18 | 1,938 | 1,948 | 1,922 | 1,944 | -4 | -0.2% | 45,000 |
2023/12/15 | 1,975 | 1,975 | 1,946 | 1,948 | -28 | -1.4% | 105,200 |
2023/12/14 | 1,981 | 1,993 | 1,968 | 1,976 | -8 | -0.4% | 37,800 |
2023/12/13 | 1,996 | 1,996 | 1,977 | 1,984 | -14 | -0.7% | 57,900 |
2023/12/12 | 2,019 | 2,024 | 1,995 | 1,998 | -22 | -1.1% | 49,700 |
2023/12/11 | 2,001 | 2,020 | 2,001 | 2,020 | +19 | +0.9% | 53,100 |
2023/12/08 | 2,022 | 2,022 | 1,991 | 2,001 | -11 | -0.5% | 99,900 |
2023/12/07 | 2,045 | 2,053 | 2,012 | 2,012 | -33 | -1.6% | 70,100 |
2023/12/06 | 2,024 | 2,049 | 2,020 | 2,045 | +23 | +1.1% | 65,900 |
2023/12/05 | 2,038 | 2,047 | 2,019 | 2,022 | -11 | -0.5% | 67,600 |
2023/12/04 | 2,040 | 2,043 | 2,015 | 2,033 | -11 | -0.5% | 73,500 |
2023/12/01 | 2,036 | 2,057 | 2,034 | 2,044 | +18 | +0.9% | 95,900 |
2023/11/30 | 2,017 | 2,032 | 2,001 | 2,026 | +12 | +0.6% | 100,700 |
2023/11/29 | 2,009 | 2,018 | 1,995 | 2,014 | +21 | +1.1% | 98,600 |
2023/11/28 | 1,970 | 1,994 | 1,958 | 1,993 | +23 | +1.2% | 74,800 |
2023/11/27 | 1,995 | 1,995 | 1,966 | 1,970 | -5 | -0.3% | 58,000 |
2023/11/24 | 1,973 | 1,975 | 1,955 | 1,975 | +22 | +1.1% | 70,700 |
2023/11/22 | 1,942 | 1,965 | 1,942 | 1,953 | +11 | +0.6% | 79,000 |
2023/11/21 | 1,923 | 1,944 | 1,918 | 1,942 | +21 | +1.1% | 69,500 |
2023/11/20 | 1,944 | 1,953 | 1,918 | 1,921 | -15 | -0.8% | 93,800 |
2023/11/17 | 1,917 | 1,936 | 1,907 | 1,936 | +32 | +1.7% | 80,700 |
2023/11/16 | 1,902 | 1,924 | 1,896 | 1,904 | +2 | +0.1% | 98,900 |
201~
250
件表示中 / 3586件
類似銘柄と比較する
現在ご覧いただいている「ゼリア新薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
ゼリア新薬 | 224,400円 | +13.6% | +29.2% | 2.05% | 11.64倍 | 1.12倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
鳥居薬 | 476,000円 | +12.0% | +28.1% | 2.52% | 26.24倍 | 1.11倍 |
|
JT傘下。柱の抗HIV薬販売権喪失後、自社製品の腎・透析、アレルゲン等の開発強化 |
持田薬 | 331,500円 | +3.0% | +27.5% | 2.41% | 20.99倍 | 0.91倍 |
|
医薬中堅。高脂血症薬、降圧薬など循環器系得意。婦人科系にも強み。消化器系育成。化粧品も |
ネクセラファーマ | 113,200円 | +197.7% | - | 0.00% | 46.26倍 | 1.48倍 |
|
創薬ベンチャー老舗。買収で成長。英国の創薬事業に日本が柱の後期治験・製造販売事業加わる |
杏林製薬 | 149,900円 | +3.2% | +4.5% | 3.47% | 17.22倍 | 0.66倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
市場注目の銘柄
チャート関連のコラム